Evidence map›Paper›PMID 39565825›Full record

ArticlePLoS computational biology2024

Learning patterns of HIV-1 resistance to broadly neutralizing antibodies with reduced subtype bias using multi-task learning.

Aime Bienfait Igiraneza, Panagiota Zacharopoulou, Robert Hinch, Chris Wymant, Lucie Abeler-Dörner, John Frater, Christophe Fraser

Abstract read
In one paragraph

Article in PLoS computational biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aime Bienfait IgiranezaPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0009-0003-2850-637X
Panagiota ZacharopoulouPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-3645-662X
Robert HinchPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-3169-698X
Chris WymantPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-9847-8226
Lucie Abeler-DörnerPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-3662-4192
John FraterPeter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-7163-7277
Christophe FraserPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-2399-9657

Funding

Wellcome Trust
6 · The paper itself

Abstract

The ability to predict HIV-1 resistance to broadly neutralizing antibodies (bnAbs) will increase bnAb therapeutic benefits. Machine learning is a powerful approach for such prediction. One challenge is that some HIV-1 subtypes in currently available training datasets are underrepresented, which likely affects models' generalizability across subtypes. A second challenge is that combinations of bnAbs are required to avoid the inevitable resistance to a single bnAb, and computationally determining optimal combinations of bnAbs is an unsolved problem. Recently, machine learning models trained using resistance outcomes for multiple antibodies at once, a strategy called multi-task learning (MTL), have been shown to improve predictions. We develop a new model and show that, beyond the boost in performance, MTL also helps address the previous two challenges. Specifically, we demonstrate empirically that MTL can mitigate bias from underrepresented subtypes, and that MTL allows the model to learn patterns of co-resistance to combinations of antibodies, thus providing tools to predict antibodies' epitopes and to potentially select optimal bnAb combinations. Our analyses, publicly available at https://github.com/iaime/LBUM, can be adapted to other infectious diseases that are treated with antibody therapy.

Indexed as

Antibodies, NeutralizingComputational BiologyHIV-1HIV AntibodiesHIV InfectionsMachine LearningBroadly Neutralizing AntibodiesEpitopesHumansAntibodies, NeutralizingBroadly Neutralizing AntibodiesEpitopesHIV Antibodies

Identifiers

PMID39565825
PMCPMC11616810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.